94 related articles for article (PubMed ID: 2361458)
1. New perspectives in medical management of hyperprolactinemia.
Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Sileo F; Ferrari L; Stroppa S; Gualteroni L; Pagani G
Endocrinol Exp; 1990 Mar; 24(1-2):159-66. PubMed ID: 2361458
[TBL] [Abstract][Full Text] [Related]
2. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia.
Merola B; Colao A; Caruso E; Sarnacchiaro F; Lancranjan I; Lombardi G; Schettini G
J Endocrinol Invest; 1992 Mar; 15(3):173-6. PubMed ID: 1624676
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.
Ciccarelli E; Miola C; Avataneo T; Camanni F; Besser GM; Grossman A
Fertil Steril; 1989 Dec; 52(6):930-5. PubMed ID: 2591571
[TBL] [Abstract][Full Text] [Related]
5. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety.
Merola B; Colao A; Caruso E; Sarnacchiaro F; Briganti F; Lancranjan I; Lombardi G; Schettini G
Gynecol Endocrinol; 1991 Dec; 5(4):267-76. PubMed ID: 1796748
[TBL] [Abstract][Full Text] [Related]
6. New long-acting bromocriptine (Parlodel MR and Parlodel LAR) in the treatment of pituitary tumours with hyperprolactinemia.
Zgliczyński W; Zgliczyński S; Makowska A; Słowinska-Srzednicka J; Janik J; Jeske W; Walecki J
Endokrynol Pol; 1992; 43(3):234-41. PubMed ID: 1345564
[TBL] [Abstract][Full Text] [Related]
7. Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study.
Moro M; Maraschini C; Toja P; Masala A; Alagna S; Rovasio PP; Ginanni A; Lancranjan I; Cavagnini F
Horm Res; 1991; 35(3-4):137-41. PubMed ID: 1806467
[TBL] [Abstract][Full Text] [Related]
8. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia.
Ciccarelli E; Ghigo E; Mazza E; Andreis M; Massara F; Lancranjan I; Camanni F
J Endocrinol Invest; 1987 Apr; 10(2):179-82. PubMed ID: 3584856
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
10. A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients.
Gianola D; Pedroncelli A; Montini M; Tengattini F; Pagani MD; Cortesi L; Cappi MP; Gherardi F; Lancranjan I; Pagani G
Gynecol Endocrinol; 1991 Sep; 5(3):213-6. PubMed ID: 1776507
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
Ciccarelli E; Giusti M; Miola C; Potenzoni F; Sghedoni D; Camanni F; Giordano G
J Clin Endocrinol Metab; 1989 Oct; 69(4):725-8. PubMed ID: 2570790
[TBL] [Abstract][Full Text] [Related]
12. Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia.
Weingrill CO; Mussio W; Moraes CR; Portes E; Castro RC; Lengyel AM
Fertil Steril; 1992 Feb; 57(2):331-5. PubMed ID: 1735484
[TBL] [Abstract][Full Text] [Related]
13. The efficacy, tolerability and safety of Parlodel LAR versus Parlodel in hyperprolactinemia.
Bolanowski M; Milewicz A; Bohdanowicz-Pawlak A; Bednarek-Tupikowska G; Jedrzejak JA; Lancranjan I
Endokrynol Pol; 1993; 44(4):467-76. PubMed ID: 8055815
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a new long-acting injectable form of bromocriptine in hyperprolactinaemic patients.
Pagani MD; Tengattini F; Montini M; Pagani G; Pedroncelli A; Gianola D; Gherardi F; Mazzocchi N; Cortesi L; Lancranjan I
Clin Endocrinol (Oxf); 1992 Apr; 36(4):369-74. PubMed ID: 1424170
[TBL] [Abstract][Full Text] [Related]
15. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
[TBL] [Abstract][Full Text] [Related]
16. [Parenteral, depot and repeatable forms of Parlodel LAR bromocriptine in the treatment of hyperprolactinemia syndrome. Comparison with oral Parlodel].
Dolecek R; Lancranjanová I; Putz Z; Vavros D; Závada M
Cas Lek Cesk; 1993 Feb; 132(3):81-5. PubMed ID: 8458069
[TBL] [Abstract][Full Text] [Related]
17. [Comparative evaluation of effectiveness of treatment of hyperprolactinemia].
Tokhunts KA
Georgian Med News; 2007 Jan; (142):14-9. PubMed ID: 17327626
[TBL] [Abstract][Full Text] [Related]
18. Tolerability, safety and efficacy of two formulations of Parlodel--a slow release oral form (SRO) versus registered Parlodel capsules.
Biberoğlu K; Atasü T; Shabgahi B; Kandemir O
Gynecol Obstet Invest; 1994; 37(1):6-9. PubMed ID: 8125413
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas.
Schettini G; Lombardi G; Merola B; Miletto P; Fariello C; Cirillo S; Fusco R; Lancranjan I
J Endocrinol Invest; 1988 Jan; 11(1):47-51. PubMed ID: 3361075
[TBL] [Abstract][Full Text] [Related]
20. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
Schettini G; Lombardi G; Merola B; Colao A; Miletto P; Caruso E; Lancranjan I
Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
